Literature DB >> 7883982

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells.

E P Feener1, J M Northrup, L P Aiello, G L King.   

Abstract

Angiotensin II (AII)- and Arg8-vasopressin (AVP)-regulated gene expression in vascular cells has been reported to contribute to vascular homeostasis and hypertrophy. In this report, AVP-induced expression of plasminogen activator inhibitor (PAI)-2 mRNA in rat microvessel endothelial (RME) cells was identified using differential mRNA display. Further characterization of vasoactive peptide effects on PAI expression revealed that AII stimulated a 44.8 +/- 25.2-fold and a 12.4 +/- 3.2-fold increase in PAI-2 mRNA in RME cells and rat aortic smooth muscle cells (RASMC), respectively. AII also stimulated a 10- and 48-fold increase in PAI-1 mRNA in RME cells and RASMC, respectively. These AII effects were inhibited by either Sar1, Ile8-angiotensin or the AT1 antagonist DuP 735, but were not significantly altered in the presence of the AT2 antagonist PD123319. AII stimulation of RASMC and RME cells also significantly increased both PAI-1 protein and PAI activity released to the culture medium. Inhibition of protein kinase C completely blocked PMA-stimulated induction of PAI-2 mRNA in both cell types and inhibited the AII-stimulated increase in RASMC by 98.6 +/- 2.8%. In contrast, protein kinase C inhibition only partially decreased the AII-stimulated PAI-2 expression in RME cells by 68.8 +/- 11.1%, suggesting that a protein kinase C-independent mechanism contributes to a 6.9 +/- 1.5-fold AII induction of PAI-2 expression in endothelial cells. AII and PMA also stimulated protein tyrosine phosphorylation in RME cells, and the tyrosine kinase inhibitor genistein partially blocked their induction of PAI-2 mRNA. These findings suggest that AII may regulate plasminogen activation in the vasculature by inducing both PAI-1 and PAI-2 expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883982      PMCID: PMC441475          DOI: 10.1172/JCI117786

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  ACE inhibitors--a cornerstone of the treatment of heart failure.

Authors:  E Braunwald
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells.

Authors:  C F Reilly; R C McFall
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

3.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO.

Authors:  J Laborda
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

4.  Influence of the angiotensin system on endothelial and smooth muscle cell migration.

Authors:  L Bell; J A Madri
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

5.  Modulation of the insulin growth factor II/mannose 6-phosphate receptor in microvascular endothelial cells by phorbol ester via protein kinase C.

Authors:  K Q Hu; J M Backer; G Sahagian; E P Feener; G L King
Journal:  J Biol Chem       Date:  1990-08-15       Impact factor: 5.157

6.  Infusion of recombinant human prorenin into rhesus monkeys. Effects on hemodynamics, renin-angiotensin-aldosterone axis and plasma testosterone.

Authors:  T Lenz; J E Sealey; R W Lappe; C Carilli; G T Oshiro; J D Baxter; J H Laragh
Journal:  Am J Hypertens       Date:  1990-04       Impact factor: 2.689

7.  Endothelin, vasopressin, and angiotensin II enhance tyrosine phosphorylation by protein kinase C-dependent and -independent pathways in glomerular mesangial cells.

Authors:  T Force; J M Kyriakis; J Avruch; J V Bonventre
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

8.  Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter.

Authors:  E Cousin; R L Medcalf; G E Bergonzelli; E K Kruithof
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

9.  Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor.

Authors:  M Mawatari; K Okamura; T Matsuda; R Hamanaka; H Mizoguchi; K Higashio; K Kohno; M Kuwano
Journal:  Exp Cell Res       Date:  1991-02       Impact factor: 3.905

10.  Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene.

Authors:  L A Erickson; G J Fici; J E Lund; T P Boyle; H G Polites; K R Marotti
Journal:  Nature       Date:  1990-07-05       Impact factor: 49.962

View more
  35 in total

1.  Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy.

Authors:  C J Friddle; T Koga; E M Rubin; J Bristow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Association between the molecular pathobiology of essential hypertension and thrombotic diseases.

Authors:  T S Edgington
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

Review 4.  Advances in understanding the peripheral circadian clocks.

Authors:  Jacob Richards; Michelle L Gumz
Journal:  FASEB J       Date:  2012-06-01       Impact factor: 5.191

Review 5.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 6.  Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia.

Authors:  Yang Xia; Susan M Ramin; Rodney E Kellems
Journal:  Hypertension       Date:  2007-06-18       Impact factor: 10.190

7.  Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants.

Authors:  A K M Tarikuz Zaman; Satoshi Fujii; David J Schneider; Douglas J Taatjes; H Roger Lijnen; Burton E Sobel
Journal:  Histochem Cell Biol       Date:  2007-06-19       Impact factor: 4.304

Review 8.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

9.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

Review 10.  Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.

Authors:  Garry X Shen
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.